Corona SP, et al. - Given that a consistent risk of relapse is seen in hormone receptor positive (HR +) breast cancer up to 15 years post-diagnosis and the use of extended adjuvant tamoxifen over 5 years is supported by increasing evidence, researchers evaluated the real effect on disease-free survival (DFS) of extended adjuvant therapy with aromatase inhibitors (AIs). For this purpose, they performed a literature-based meta-analysis of randomized controlled trials. They identified relevant studies from PubMed, the Cochrane Library, and abstracts from the American Society of Clinical Oncology and San Antonio Breast Cancer symposia. With a 22% increase in DFS, extended adjuvant treatment with AIs was shown to be efficacious for HR + early breast cancer in this study, however, overall survival remained unchanged. Women with positive nodal status experienced greater efficacy.